ArticleAging pathobiology and therapeutics2024
The naturally occurring peptide GHK reverses age-related fibrosis by modulating myofibroblast function.
Article in Aging pathobiology and therapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Fibrotic disorders, such as idiopathic pulmonary fibrosis, are characterized by the accumulation of myofibroblasts, cells responsible for excessive extracellular matrix deposition and tissue remodeling. The inability to terminate this reparative process leads to persistent fibrosis with increasing age. GHK (glycyl-L-histidyl-L-lysine], a naturally occurring peptide, has demonstrated the potential in modulating fibrotic pathways by reversing cellular senescence and inducing apoptosis in myofibroblasts. GHK promotes tissue regeneration and enhances wound healing by activating stemness markers like p63 and PCNA. In aging, GHK's effect on pulmonary fibroblasts may restore youthful phenotypes, improving fibroblast migration and collagen contraction. This commentary discusses the role of GHK in resolving persistent fibrosis and the molecular mechanisms underpinning these effects, including integrin-β1 signaling. The potential of GHK as a therapeutic agent for fibrosis, including combination strategies with antioxidants or anti-inflammatory agents, is also explored.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.